CollabRx teams up with OncoDNA
SAN FRANCISCO—Data analytics firm CollabRx, Inc. and Belgian company OncoDNA, SA, a provider of DNA next-generation sequencing tests for clinical use in cancer, have announced the beginning of a multi-year agreement to buy CollabRx software as a service-based technology and content resources, which will be used in conjunction with OncoDNA's cancer mutation panels.
Per the agreement, the partners will undertake the development of a combined test and medical informatics solution by uniting the results of OncoDNA-developed cancer mutational panels with clinically actionable knowledge from CollabRx, which currently boasts a network of more than 75 leading clinical practitioners in the United States and Europe. No financial terms for the agreement were disclosed.
"Our agreement with OncoDNA reflects our commitment to partner with best- in-class laboratories and diagnostic companies, and is a significant step forward in our strategy to serve high-growth markets outside of the U.S.," Thomas Mika, chairman, president and CEO of CollabRx, commented in a press release. "We are excited to work with OncoDNA to establish a leadership position in the clinical next-generation sequencing market in Europe by providing ordering physicians with clinically relevant interpretation of test results as a seamless part of the reporting process."
This partnership is the first for CollabRx outside of the United States. The company's approach includes a semantic integration platform, which allows for dynamic updates of CollabRx's molecular oncology knowledge base with the latest medical and scientific data from the public domain.
"NGS-based tests are increasingly becoming a routine part of clinical care for cancer patients, but the complexity of the genetic data from tumor mutations is outpacing the ability of physicians to stay current with advanced treatments. We are excited to partner with CollabRx to close this knowledge gap and enable physicians who order OncoDNA tests to access highly credible knowledge provided by CollabRx to aid in the interpretation of test results," said Jean-Pol Detiffe, founder and CEO of OncoDNA, in a press release regarding the deal.
The announcement for the CollabRx/OncoDNA agreement comes one month to the day after another CollabRx partnership, which was announced with Projects In Knowledge, Inc., a developer of point-of-care digital and mobile information tools. The two organizations announced a multi-year partnership for the joint distribution of informational point-of-care software applications to the more than 35,000 oncologists and clinicians that make up Projects In Knowledge's clinician network.
Under the terms of the partnership, CollabRx and Projects In Knowledge will initially work to integrate CollabRx Therapy Finder products into the Projects In Knowledge @Point of Care360 platform, a next-generation interactive medical textbook that offers point-of-care accessibility. Therapy Finder applications consist of decision-support tools that provide oncologists and pathologists with the ability to factor in the genetics of a patient's tumor during the treatment planning process. Financial terms were not released.
SOURCE: CollabRx press release